Uncovering the Potential of CD40 Agonism to Enhance Immune Checkpoint Blockade.
Clin Cancer Res
; 30(1): 9-11, 2024 01 05.
Article
em En
| MEDLINE
| ID: mdl-37870487
ABSTRACT
In this CCR Translations, we discuss the therapeutic potential of CD40 agonism, which stimulates antigen-presenting cells (APC) to activate effector T and NK cells. CD40 agonism may lead to development of an interferon-activated, T cell-inflamed tumor microenvironment and has the potential to facilitate long-term response with immune checkpoint blockade. See related article by Weiss et al., p. 74.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antígenos CD40
/
Inibidores de Checkpoint Imunológico
Limite:
Humans
Idioma:
En
Revista:
Clin Cancer Res
Assunto da revista:
NEOPLASIAS
Ano de publicação:
2024
Tipo de documento:
Article